Injectables account for more than half of the minimally invasive procedures performed today. Before Restylane (Medicis, restylaneusa.com), the first non-animal-based hyaluronic acid (HA) dermal filler, was introduced in the United States in 2003, botulinum toxin was the most popular injectable in aesthetic medicine. Today, Botox has taken a backseat in growth to HA injections, which have increased to...
Articles
“Fractional lasers have become the go-to instruments for skin rejuvenation and scar...
Injectables account for more than half of the minimally invasive procedures performed...
Mirvaso (Galderma Laboratories, galderma.com) has become the first topical drug to...
Perhaps you’ve experienced one of these scenarios: You receive an angry email from a...
Products
SkinCeuticals Advanced Pigment Corrector clears and brightens skin by...
The Lutronic INFINI fractional radiofrequency-based system has received FDA...
Edge Systems HydraFacial Daily Essentials help patients maintain the results...
The InMode Aesthetic Platform from InMode Aesthetic Solutions allows...
The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD).
The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, a protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using narrow pathway-targeted immune interventions for not just AD, but also other “allergic” inflammatory diseases of the skin or other organs, such as asthma.
Emma Guttman, MD, PhD, associate professor of dermatology, and director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, professor and chair of dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial.
Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22...
Chad Hivnor, MD, of HealthCrave Medical Centers has received the Paul W. Myers Award. Formally known as the Clinical Surgeons Award, the Paul W. Myers Award is reserved for the Air Force medical corps officer who has made significant contributions in the health care of men and women serving in the United States Air Force.
Dr. Hivnor received extensive training in laser medicine and surgery and has treated many wounded warriors and specializes in scar treatment. He graduated from the U.S. Air Force Academy with a BS in Biochemistry, with distinguished honors, before attending the University of Texas Health Science Center, where he received his medical degree. Dr. Hivnor completed his residency in dermatology at the University of Pennsylvania, then returned to San Antonio, where he served as staff dermatologist at Lackland Air Force Base.
As one of the nation's foremost laser experts in the country, Dr. Hivnor has performed extensive research in lasers, cosmetics, onychomycosis, skin cancer and scars. He was awarded a $1.1 million dollar grant to collaborate with Harvard University to study lasers’ effects on scars and functional improvement after scars and surgery.
The American Academy of Dermatology (AAD) has released a list of five specific treatments and procedures related to skin health and care that are not always necessary. The list was developed as part of the ABIM Foundation’s (www.abimfoundation.org) Choosing Wisely initiative, which was developed to reduce the overuse of unnecessary medical tests and procedures by encouraging dialogue between patients and physicians.
The recommendations—which were developed by an Academy workgroup comprised of board-certified dermatologists and reviewed and approved by the Academy’s Council on Science and Research and the Academy’s Board of Directors—include:
1. Don’t prescribe oral antifungal therapy for suspected nail fungus without confirmation of a fungal infection. Approximately half of all patients with suspected nail fungus do not have a fungal infection.
2. Don’t perform sentinel lymph node biopsy or other diagnostic tests for the evaluation of early, thin melanoma because they do not improve survival. The five-year survival rate for patients with these types of melanoma is 97%, and there is a low risk of the cancer spreading to other parts of...
